Medical devices — US PTAB Patent Cases
522 decisions indexed
Page 17 of 18 · 522 total
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott challenges DexCom's CGM patent (US 10375222) in an IPR, asserting that the claims are obvious over multiple prior art combinations. The petition was instituted by the Board after finding compelling evidence of unpatentability.
NULIDS, LLC v.BlephEx, LLC
NULIDS, LLC and BlephEx, LLC settled their IPR dispute before trial, leading the Board to dismiss the petition and terminate the proceeding.
NULIDS, LLC v.BlephEx, LLC
NULIDS challenges BlephEx's patent (11083621) in an IPR petition, arguing that the device for ocular disorder treatment is obvious. The petitioner relies on combinations of prior art references including Grenon I, Grenon II, Nichamin, Colin, and Shabo to invalidate claims 1-6, 9-18.
Cala Health, Inc. v.EMKinetics, Inc.
The PTAB issued an order in IPR2024‑00732 and IPR2024‑00743 requiring Cala Health and EMKinetics to file a true copy of their settlement agreement before the proceedings can be terminated.
Cala Health, Inc. v.EMKinetics, Inc.
Cala Health and EMKinetics filed a joint request asking the PTAB to keep their settlement agreement confidential under 35 U.S.C. §317, citing competitive harm if disclosed. The Board has yet to rule on the request.
Cala Health, Inc. v.EMKinetics, Inc.
The PTAB issued an order compelling Cala Health and EMKinetics to file a true copy of their settlement agreement before the joint motion to dismiss can be acted upon, emphasizing compliance with 37 C.F.R. § 42.74(b). A dissenting judge argues the rule does not apply pre‑institution.
Cala Health, Inc. v.EMKinetics, Inc.
Cala Health and EMKinetics settled their dispute over two patents, filing a joint motion that led the PTAB to terminate the IPRs before any trial was instituted.
Cala Health, Inc. v.EMKinetics, Inc.
Cala Health challenges EMKinetics' patent on tremor treatment using electrical stimulation, arguing that prior art references Gesotti and Burnett render all claims obvious or anticipated. The petitioner details how these older devices satisfy every limitation of the claimed apparatus and method for treating neurological conditions like tremor.
Cala Health, Inc. v.EMKinetics, Inc.
Cala Health challenges the validity of EMKinetics' '669 patent by asserting that its claims are anticipated or obvious over prior art references, primarily Gesotti and Burnett. The petitioner argues that the claimed technology for tremor treatment is already disclosed in the prior art, presenting multiple grounds under 35 U.S.C. §§ 102 and 103.
Intersect ENT, Inc. et al. v.New Amsterdam, LLC
Intersect ENT and New Amsterdam, LLC have entered a settlement that resolves all disputes over U.S. Patent 6,916,483. They jointly moved to terminate the inter partes review, citing the settlement and lack of further contest.
Intersect ENT, Inc. et al. v.New Amsterdam, LLC
Intersect ENT and New Amsterdam settled their IPR dispute over U.S. Patent 6,916,483, filing a joint motion that led the PTAB to terminate the proceeding before trial.
Intersect ENT, Inc. et al. v.New Amsterdam, LLC
Intersect ENT, Inc. filed a Petition challenging all 20 claims of Medtronic's '483 Patent based on obviousness (103). The Petitioner argues that combinations of prior art references—including Watson and Schwartz—render the implantable drug delivery device unpatentable.
Avation Medical, Inc. v.EMKinetics, Inc.
Avation Medical’s IPR resulted in claims 1‑13 of U.S. Patent 11,224,742 being found unpatentable. EMKinetics sought Director Review, re‑asserting printed‑publication arguments, but the Board denied the request, upholding its decision.
Avation Medical, Inc. v.EMKinetics, Inc.
Avation Medical has filed an IPR petition challenging EMKinetics' U.S. Patent 11,224,742 covering non‑invasive posterior tibial nerve stimulation for overactive bladder. The petition argues the claims are obvious over prior‑art references such as Svihra, Amarenco, Mann and Ponsford and seeks institution of the trial.
Avation Medical, Inc. v.EMKinetics, Inc.
The PTAB found all 13 challenged claims unpatentable under 35 U.S.C § 103. The Board concluded that the claimed nerve stimulation therapy was obvious over combinations of prior art, specifically citing modifications to Svihra and Amarenco using Mann and Ponsford. This decision confirms the lack of inventive step for the technology described in the patent.
Catalyst OrthoScience Inc. v.Shoulder Innovations, Inc.
Catalyst OrthoScience seeks a PTAB post‑grant review of Shoulder Innovations' reverse shoulder implant patent, arguing obviousness over multiple prior‑art references and indefiniteness of the term “central channel.” The petition also asserts that discretionary denial is unwarranted.
Catalyst OrthoScience Inc. v.Shoulder Innovations, Inc.
Catalyst OrthoScience Inc.'s Post-Grant Review petition against Shoulder Innovations, Inc. was denied by the PTAB. The Board found that Petitioner failed to establish a 'compelling merits' showing for either obviousness (103) or indefiniteness (112).
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom have filed a joint motion to terminate IPR2024-00853 after reaching a confidential settlement and license agreement, invoking 35 U.S.C. § 317(a). The Board has not yet decided the merits, and the parties seek to end the proceeding.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom have filed a joint request to keep their settlement agreement confidential, invoking statutory provisions that allow business‑confidential treatment of settlement documents.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom have entered into a confidential settlement and license agreement and jointly moved to terminate IPR2024-00840 under 35 U.S.C. §317(a). The Board has not yet decided the merits, satisfying the statutory criteria for termination.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom settled their IPR dispute, leading the PTAB to terminate the proceeding. The settlement agreement was deemed confidential business information.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom filed a joint request to keep their settlement agreement confidential, invoking Section 317(b) and related regulations. The request seeks to separate the settlement from the public patent file.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom settled their dispute over DexCom’s glucose‑monitoring patent, leading the PTAB to terminate the IPR. The settlement agreement was deemed confidential business information.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. filed a Petition challenging 24 claims of DexCom's '528 patent, asserting anticipation and obviousness. The challenge focuses on the combination of real-time user settable low glucose alarms with predicted non-user settable low glucose alarms in CGM systems.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
The petitioner asserts that U.S. Patent No. 11,679,077 is invalid due to anticipation and obviousness over multiple prior art references in the field of nasal therapy. The core arguments focus on how Saadat anticipates key claims, while combinations of Makower, Fang, and Edwards-535 render other claims obvious.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
NEURENT MEDICAL INC. successfully petitioned PTAB for institution of IPR against THE FOUNDRY, LLC's nasal cavity treatment patent (11679077). The Board found sufficient evidence across multiple grounds of anticipation and obviousness to proceed to trial.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
The Petitioner successfully demonstrated that multiple claims of the '077 patent were unpatentable over various combinations of prior art references. The Board found that a Person Having Ordinary Skill in the Art (POSA) would have been motivated to combine existing RF ablation and nasal treatment technologies.
3Shape A/S et al. v.Dental Imaging Technologies Corporation
Petitioner asserts that the challenged dental imaging claims are obvious over various combinations of prior art references, including Sommer, Rubbert, Malfliet, and Estépar. The petition details how specific elements related to bite registration methods merely aggregate known technologies from these sources.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom, Inc. initiated this IPR petition against Abbott Diabetes Care Inc.'s patent, challenging multiple claims based on obviousness. The core argument is that the patented features are merely predictable combinations of prior art references (Stafford, Raymond, and Turner).
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom failed to convince the PTAB that Abbott's glucose monitoring patent was unpatentable based on obviousness grounds. The Board denied institution, finding insufficient evidence across multiple prior art combinations.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.